Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To characterize basic fetoprotein (BFP) as a new tumor marker, we measured serum levels of BFP and 5 other tumor markers (CA19-9, CEA, NSE, SCC, and TPA) concomitantly in 65 patients with lung cancer, 57 patients with benign pulmonary disease, and 40 healthy volunteers. The sensitivity of BFP was 43%, the specificity 82% and the accuracy 61%. The positivity increased in relation to stage of the disease. There was no correlation between positivity of BFP and histologic type. On the whole, BFP appeared to be analogous to TPA in terms of broad spectrum and to have an auxiliary value in diagnosing lung cancer.
 ...
PMID:Preliminary study on auxiliary value of serum basic fetoprotein in diagnosing lung cancer. 174 51

To evaluate the usefulness of tumor-associated trypsin inhibitor (TATI) as a marker for the diagnosis of lung cancer we determined serum levels of this peptide in 255 patients with lung cancer and in 74 patients with chronic obstructive lung disease. A reference population consisting of 151 healthy volunteers was also studied. TATI concentrations were measured by radioimmunoassay. As a cut-off point we used the 99th percentile of the TATI concentrations in a reference population, which was 32 micrograms/l. TATI does not appear to be a good tumor marker in lung cancer. Its sensitivity is poor in comparison with CEA and TPA. The correlation between TATI levels and stage of the disease and histological type was weak.
 ...
PMID:Tumor-associated trypsin inhibitor (TATI) in the diagnosis of lung cancer. 178 Jun 95

Basing on results of tumor marker levels (CEA, ferritin, orosomucoid) in 271 lung cancer patients and 50 with non-malignant pulmonary diseases the authors found that assessment of different tumor markers is clinically more useful than single marker evaluation. Analysing several markers increases the specificity to almost 100% but decreases the sensitivity. Assessing several markers can help differentiating between malignant and non-malignant pulmonary disorders. It may also help in correctly staging the disease. A 12 month survival rate was seen only in 50% of the patients in whom the levels exceeded the cut-off value of two studied markers, whereas 90% survived 12 months if all marker levels were within normal levels. None of the patients with all markers exceeding the normal values survived one year after surgery. Survival rates of patients treated non-surgically were not influenced by the tumor marker levels.
 ...
PMID:[Usefulness of simultaneous antigenic determination of carcinoembryonic antigen (CEA), ferritin and orosomucoid levels in diagnosis of lung neoplasms]. 184 46

Three interesting cases of primary lung cancer from the standpoint of tumor marker production were reported. The first was a case of double cancers, one of which was sigmoid cancer without CEA production and the other a large cell lung cancer with CEA production. The evidence of elevated serum CEA level initially led to a wrong diagnosis as sigmoid cancer with lung metastasis. The second was a case which showed a relapse of monotonous cancer without CEA production after surgical removal of lung cancer tissue containing heterogeneous cancer cells. Elevated serum CEA levels were never observed after the operation, although the preoperative serum test was positive for CEA. The last was a case of squamous cell lung cancer which showed trophoblastic differentiation accompanied with massive hCG production. Very rapid tumor cell growth was seen after the early relapse following the operation. Positivity for hCG staining varied among primary and metastatic tumor tissues.
 ...
PMID:[Tumor markers--personal experience. A case report of primary lung cancer with interesting production of tumor markers]. 187 30

Immunoscintigraphy with 111In-labeled anti-CEA-Mab (F023C5i) was carried out in 66 patients strongly suspected for a primary lung cancer and in 8 control patients suffering from different chest diseases. A sensitivity of 0.90, a specificity of 0.45 and an accuracy of 0.85 were calculated. False-negative results were mainly obtained in patients in whom the size of the lesion was below 2 cm and the tumor was centrally located. All patients affected by small-cell carcinoma were correctly identified. In 89% of the patients, a positive immunoscintiscan was associated with the presence of the antigen in the tumor. False-positive results were observed in control patients suffering from different chest diseases due to the nonspecific uptake of the tracer. The tumor definition was generally better after 120 hr than at an earlier time after injection due to the reduction of background activity. SPECT imaging defined the tumor better in each patient but did not reveal any tumor not seen on planar studies.
 ...
PMID:Detection of suspected primary lung cancer by scintigraphy with indium-111-anti-carcinoembryonic antigen monoclonal antibodies (type F023C5) 194 Nov 40

The significance of neuron specific enolase (NSE) was investigated in comparison with other tumor markers (CEA, CT, CA 15-3) used in the diagnosis and treatment monitoring of lung cancer. As previously described, the calcitonin assay proved to have very low sensitivity for small cell lung cancer (SCLC). The serum NSE assay was, however, shown to be a useful diagnostic aid for discrimination between histologically different lung cancers, and therefore this assay may be a valuable tool for treatment monitoring in SCLC patients. CA 15-3, also an unspecific marker, showed similar sensitivity to the NSE assay in SCLC patients, the sensitivity being higher than CEA in non small cell lung cancer (NSCLC).
 ...
PMID:Serum NSE, CEA, CT, CA 15-3 levels in human lung cancer. 196 44

The content of the epidermal growth factor receptor (EGFr) and its relation to tissue CEA and NSE were examined in 22 intracranial neoplasms (18 primary intracranial tumors and 4 metastasis from lung cancer). The EGFr was measured by a radioligand assay on crude plasma membrane preparations. The tissue tumor markers (CEA and NSE) were measured on the high speed supernatant of tissue homogenates. In the primary intracranial tumors the EGFr was positive in 68%, CEA in 43% and NSE in 47% of all cases examined. As it concerns the metastasis from lung cancer the positivity was 75% for EGFr while for CEA and NSE was 50% and 32% respectively. These results suggest that the routine measurement of EGFr, associated with the determinations of tissue CEA and NSE could provide useful information on the type of the intracranial neoplasms.
 ...
PMID:Epidermal growth factor receptor and tissue tumor markers in human intracranial neoplasms. 196 99

Macro creatine kinase type 2 (MCK-2), an atypical cathodically migrating creatine kinase isoenzyme, was first detected in the serum of a breast cancer patient in 1978. In recent years, MCK-2 was also found in the sera of several malignancies and has been proposed as a potential tumor marker. Forty two patients with lung cancer. The rates of MCK-2 presence in serum were 56.8%, 29.6%, and 0%, respectively, for primary lung cancer, inflammatory lung disease and normal controls. In primary lung cancer, the rate of presence of MCK-2 was higher than CEA (40.0%), and appeared more frequently in epidermoid cancer (71.3%) and in stages 3 and 4 (65.4%). Serial examinations postoperatively showed that MCK-2 became negative after resection. Carcinoembryonic antigen, MCK-2 or a combination of both was evaluated as a diagnostic aid in 37 patients with a peripheral pulmonary nodule. Sensitivity, specificity and accuracy were 32.0%, 90.9%, 50.0%, 36.4%, 93.3%, 59.5%; 43.8%, 90.5%, 70.3%, respectively, for CEA, MCK-2, and CEA plus MCK-2. It is concluded that MCK-2 is comparable to CEA as a tumor marker in lung cancer. The combination of MCK-2 and CEA is of value as a diagnostic aid in patients with a peripheral pulmonary nodule.
 ...
PMID:Serum macro creatine kinase type 2 as a tumor marker in lung cancer: comparison with carcinoembryonic antigen. 197 16

Five tumor markers (CA19-9, CEA, NSE, SCC, TPA) were measured concomitantly in the serum of 128 patients with primary lung cancer (LC), 148 patients with benign disease (B) and 43 normal volunteers. The positive rates for all the tumor markers were significantly higher in the LC group than in the B group. When multiple tumor markers were quantitated, the specificity for the detection of lung cancer became lower although the sensitivity increased. However, this negative point was made up for to some extent by evaluating the number of positive markers. In monitoring the clinical course, independent changes were observed in markers in some cancer patients. These results implied that measuring multiple tumor markers was of clinical value in monitoring the clinical course of cancer patients as well as in assisting the diagnosis of lung cancer.
 ...
PMID:Clinical evaluation of five tumor marker assay in patients with lung cancer. 201 88

We analyzed 15 patients with small but advanced primary lung cancer operated from 1965 to 1988. The size of tumors were less than 2.0 cm in largest dimension and their pathological stages III A, III B and IV. The histological types were adenocarcinoma in 13 cases and squamous cell carcinoma in 2 cases. Nine patients (69%) had elevated levels of preoperative serum CEA. The prognosis of patients with intrapulmonary metastases was better than that of those with pleural dissemination. In adenocarcinoma patients with mediastinal lymph node metastases, the survival rate of cases with small cancer less than 2.0 cm in diameter was higher than those with large cancer more than 5.0 cm in diameter.
 ...
PMID:[Study of surgical treatment of advanced small lung cancer]. 203 42


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>